NTI164 to be presented at IRSF Annual Scientific Meeting

ASX Announcement Neurotech International Ltd Suite 5 CPC, 145 Stirling Highway Nedlands, Western Australia 6009 T: +61 (8) 9389 3130 E: [email protected] W: neurotechinternational.com ABN: 73 610 205 402 ASX: NTI 1 of 2 6 June 202 5 NTI164 to be presented at International Rett Syndrome Foundation Annual Scientific Meeting Neurotech International Limited (ASX: NTI) (“Neurotech” or “the Company”), a clinical - stage biopharmaceutical company focused on paediatric neurological disorders, is pleased to announce that its lead product NTI 164 will be highlighted in presentation s at the upcoming International Rett Syndrome Foundation (IRSF) Scientific Meeting . The event is being held 9 - 11 June 2025 in Boston, USA with a ttendees representing academia, industry, and governmental agencies present emerging data and insights about the most pressing issues surrounding Rett Syndrome . Neurotech’s Principal Investigator for the Rett Study , Professor Carolyn Ellaway, will be in attendance to deliver both an oral and poster presentation regarding NTI164. The poster, titled ‘A novel full - spectrum medicinal cannabis biopharmaceutical (NTI164) improves symptoms of Rett Sy n drome – a Phase I/II clinical trial’ , will be presented during the poster session on Monday 9 June from 5 - 7pm (US EST) . Professor Ellaway will then conduct an oral presentation , titled ‘Full spectrum medicinal cannabis in Rett syndrome: Results of an open - label Phase 1/2 clinical trial’ at 9:55am (US EST) Wednesday 11 June as part of the Industry Updates segment of the event . For more information on the event, please visit: https://www.rettsyndrome.org/researchers/annual - rett - syndrome - scientific - meeting/ This announcement has been authorised for release by the board of Neurotech International Limited. For further information contact us via [email protected] About Neurotech Neurotech International Limited (ASX:NTI) ) is a clinical - stage biopharmaceutical development company focused predominately on paediatric neurological disorders with a broad - spectrum oral cannabinoid drug therapy called NTI164 . Neurotech has completed a Phase II/III randomised, double - blind, placebo - controlled clinical trial in Autism Spectrum Disorder (ASD) with clinically meaningful and statistically significant benefits reported across a number of clinically - validated measures and excellent safety. In addition, Neurotech has completed and reported statistically significant and clinically meaningful P hase I/II trials in ASD and Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute - Onset Neuropsychiatric Syndrome (PANS), collectively PANDAS/PANS along with Rett Syndrome. Neurotech has re ceived human ethics committee clearance for a Phase I/II clinical trial in spastic cerebral palsy. For more information about Neurotech please visit http://www.neurotechinternational.com . Neurotech International Ltd Suite 5 CPC, 145 Stirling Highway Nedlands, Western Australia 6009 T: +61 (8) 9389 3130 E: [email protected] W: neurotechinternational.com ABN: 73 610 205 402 ASX: NTI 2 of 2 About NTI164 NTI164 is a proprietary drug formulation derived from unique cannabis strains with a novel combination of cannabinoids including CBDA, CBC, CBDP, CBDB and CBN. C linical studies have demonstrated a potent anti - proliferative, anti - oxidative, anti - inflammatory and neuro - protective effects in human neuronal and microglial cells. NTI164 is being developed as a therapeutic drug product for a range of neurological disord ers in children where neuroinflammation is involved.

The release as fetched from its publisher. investi.com.au ↗